Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp online chat

	NCI Highlights


	Maintenance Rituximab for Follicular Lymphoma Azacitidine Improves Survival in MDS Second Stem Cell Transplant Not Helpful in Myeloma

Arthralgia During Anastrozole Therapy for Breast Cancer

Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs
Phase IV Treatment Closed 18 and over Pharmaceutical / Industry D5392L00013
2005-00-5441-19 EUDRACT number, NCT00323479

Trial Description

Summary

The purpose of this study is to describe the joint symptoms and structural joint changes under anastrozole as adjuvant treatment in postmenopausal women with early breast cancer.

Eligibility Criteria

Inclusion Criteria:

Post menopausal woman with a breast cancer and scheduled for an adjuvant treatment with anastrozole

WHO performance status 0, 1 or 2

Provision of written informed consent

Exclusion Criteria:

Recurrence of breast cancer, inflammatory rheumatism

treatment by chondromodulator, oral glucocorticoid, aromatase inhibitor, anti estrogen, Herceptin

Diabetes treated by insulin

Severe renal or hepatic disease

Known hypersensitivity to anastrozole

Trial Contact Information

Trial Lead Organizations/Sponsors

AstraZeneca Pharmaceuticals LP

AstraZeneca France Medical Director, MD

Study Director

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00323479
Information obtained from ClinicalTrials.gov on March 18, 2009

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.